Daljeet Singh Kohli, Head of Reresearch at India Nivesh Securites recommends buying Jubilant Life Sciences with a target of Rs 492.
first published: Dec 2, 2015 03:10 pm
A collection of the most-viewed Moneycontrol videos.
Nifty Snaps 6-Day Winning Streak As Markets Get In Consolidation Mode| Closing Bell Live
Kenneth Andrade picks three unusual, ignored sectors to bet on in Samvat 2082
Nifty Likely To Consolidate Until It Clears 26,000 Mark Decisively | Opening Bell Live
Nifty Slips Over 150 Points From Day's High But Gains For 6th Day| IT Stocks Surge|Closing Bell Live
You are already a Moneycontrol Pro user.